Crinetics Pharmaceuticals CRNX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$465.32M-55.9% | -$298.41M-39.1% | -$214.53M-30.9% | -$163.92M-52.3% | ||
| $3.89M+39.7% | $2.79M+154% | $1.1M+11.7% | $983K+6.6% | ||
| $91.02M+31.2% | $69.39M+69.5% | $40.94M+44.8% | $28.27M+62.9% | ||
| -$377.92M-64.2% | -$230.19M-36.5% | -$168.6M-46.3% | -$115.21M-30.0% | ||
| $5.76M+49.9% | $3.84M-18.0% | $4.69M+183% | $1.66M+280% | ||
| $173.91M+129% | -$595.42M-197% | -$200.41M— | —— | ||
| $40.61M-96.0% | $1.01B+159% | $391.24M+221% | $121.96M-51.7% | ||
| —— | —— | —— | -$168.98M— | ||
| -$383.68M-63.9% | -$234.04M-35.1% | -$173.29M-48.3% | -$116.86M-31.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Crinetics Pharmaceuticals's cash flow data come from?
- Every line is extracted from Crinetics Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.